|
[
Life Sciences ]
MACROMOLECULAR
STRUCTURES FOR BORON NEUTRON-CAPTURE THERAPY
Participating UCLA Researchers:
Robert R. Kane, M.Frederick Hawthorne
A general synthetic method has been developed for the rapid and efficient
production of a variety of boron-rich macromolecules suitable for conjugation
with inclusion in receptor-mediated delivery systems as well as other
delivery systems. Preparation techniques have been developed to yield
precisely ordered oligophosphates which are soluble, and hydrophilic.
These molecules, may also be homogeneous, and may be prepared with a variety
of functional groups.
U.S. Patent No. 6,248,916
B1
U.C. Case No. 1992-573-4
Issued: June 19, 2001
LEAFY
COTYLEDONI GENES AND METHODS OF MODULATING EMBRYO DEVELOPMENT IN TRANSGENIC
PLANTS
Participating UCLA Researchers:
Robert B. Goldberg
The present invention provides nucleic acid sequences from LEAFY COTYLEDONI
(LECI) genes encoding LECI polypeptides which comprise a CCAAT binding
factor domain and which modulate embryo development in plants. The nucleic
acids are useful in inducing ectopic development of embryonic tissue or
in modulating embryo development in transgenic plants.
U.S. Patent No. 6,235,975
U.C. Case No. 1997-177-3
Issued: May 22, 2001
CONSERVED
ANTI-DNA ANTIBODY IDIOTYPE ASSOCIATED WITH NEPHRITIS IN MURINE AND HUMAN
LUPUS
Participating UCLA Researchers:
Richard Weisbart
Methods and antibody compositions are provided for the diagnosis and treatment
of lupus nephritis. By employing B-cells of a lupus nephritis host with
a fusion partner, antibodies can be obtained, which may serve as immunogens
for the production of antiidiotypic antibodies, which may then be used
for diagnosis and therapy of lupus nephritis.
U.S. Patent No. 6,232,444
B1
U.C. Case No. 1990-548-2
Issued: May 15, 2001
ANTIBODIES
TO S. MUTANS AND USES THEREOF
Participating UCLA Researchers:
Wenyuan Shi, Wyatt R. Hume
The invention describes three monoclonal IgG antibodies, referred to as
SWLA1, SWLA2, and SWLA3, which appear to recognize a species-specific
lipo-oligosaccharide or lipo-polysaccharide on the cell surface of S.
mutans. The invention also describes a rapid method of detection of
S. mutans without the need for prior growth of the bacteria in
culture. The invention further describes a method of utilizing these antibodies
for rapidly quantitatively detecting S. mutans. These methods are
sensitive enough to detect the presence of a single S. mutans bacteria
cell. These methods can be widely used in the clinical diagnosis and treatment
of dental caries in humans.
U.S. Patent No. 6,231,857
B1
U.C. Case No. 1998-559-3
Issued: May 15, 2001
METHOD
FOR REDUCING BCL-2 EXPRESSING CELLS RESISTANCE TO DEATH
Participating UCLA Researchers:
Dale E. Bredesen
The present invention involves methods for controlling cell death when
the cell is exposed to one or more potentially lethal cellular insults.
In one method, cell death is inhibited by introducing a reactive oxygen
species limiter into the cell. This process prevents the build up of lethal
levels of reactive oxygen species when the cell is exposed to a cellular
insult. In another method, cell death is promoted in cancer cells or other
proliferating cells that are naturally resistant to lethal cellular insults.
The method involves neutralizing reactive oxygen species limiters, such
as bcl-2, that are present in cancer cells. This process impairs bcl-2's
activity in limiting reactive oxygen species inhibits the ability of a
cancer cell to protect itself when cellular insult causes increases in
the level of reactive oxygen species. The result is an increase in cell
death.
U.S. Patent No. 6,231,852
B1
U.C. Case No. 1993-581-3
Issued: May 15, 2001
NUCLEIC
ACIDS THAT CONTROL ENDOSPERM DEVELOPMENT IN PLANTS
Participating UCLA Researchers:
Robert B. Goldberg
The invention provides methods of controlling endosperm development in
plants.
U.S. Patent No. 6,229,064
U.C. Case No. 1998-251-3
Issued: May 8, 2001
METHOD
AND KIT FOR OBTAINING FLUIDS AND CELLULAR MATERIAL FROM BREAST DUCTS
Participating UCLA Researchers:
Susan M. Love
Methods, kits, and apparatus for obtaining cellular, chemical, and other
materials from breast ducts are described. A single milk duct is accessed
and washed with a washing fluid to obtain marker materials from the lining
the duct. The washing fluid is then collected, and the marker materials
in the washing fluid identified and analyzed. Usually, the washing fluid
is introduced using a syringe through a lumen of a dual-lumen catheter.
The ductal volume is filled with the washing fluid and excess fluid flows
outwardly through a second lumen of the dual-lumen catheter, from which
it is collected.
U.S. Patent No. 6,221,622
B1
U.C. Case No. 1998-549-1
Issued: April 24, 2001
TRANSCRIPTIONALLY
REGULATED G PROTEIN-COUPLED RECEPTOR
Participating UCLA Researchers:
Zhigang Weng, Owen N. Witte
A G protein-coupled receptor (GPCR), called G2A, whose expression is regulated
and functions at the G2/M check-point to ensure properly controlled duplication
of hematopoietic cells. The receptor is found predominantly in hematopoietic
cells and tissues and functions as a tumor suppressor gene and induces
cell cycle arrest. This receptor may play an important role in regulating
the proliferation and differentiation of hematopoietic cells. Regulation
of receptor activity has several therapeutic applications.
U.S. Patent No. 6,214,562
B1
U.C. Case No. 1997-538-2
Issued: April 10, 2001
IDENTIFICATION
OF A G PROTEIN-COUPLED RECEPTOR TRANSCRIPTIONALLY REGULATED BY PROTEIN
TYROSINE KINASE SIGNALING IN HEMATOPOIETIC CELLS
Participating UCLA Researchers:
Zhigang Weng, Owen N. Witte
A G protein-coupled receptor (GPCR) which is activated by oncogenes. The
receptor is found predominantly in hematopoietic cells and tissues and
functions as a tumor suppressor gene and induces cell cycle arrest. This
receptor may play an important role in regulating the proliferation and
differentiation of hematopoietic cells. Regulation of receptor activity
has several therapeutic applications.
U.S. Patent No. 6,207,412
B1
U.C. Case No. 1997-538-1
Issued: March 27, 2001
METHODS
FOR THE DIAGNOSIS AND TREATMENT OF INSULIN-DEPENDENT DIABETES MELLITUS
Participating UCLA Researchers:
Daniel L. Kaufman, Jide Tian
Methods for detecting the status of an insulin-dependent diabetes mellitus
(IDDM)-associated autoimmune response in a mammal are provided. Specifically,
the ratio of the frequency of T helper 1 cells to T helper 2 cells specific
for a pancreatic beta-cell associated antigen is indicative of the status
of the autoimmune response. The methods may be employed prior to the onset
of the clinical symptoms of the disease, thereby allowing identification
of those at risk for developing clinical symptoms of IDDM, or subsequent
to pancreatic tissue transplantation, for example, to measure the efficacy
of treatment directed to enhancing the lifetime of the tissue transplant.
Methods for prolonging the survival of tissue transplants are also provided.
Specifically, a tissue-associated antigen is administered to the mammal
which serves to shift the pathogenic Th1 response associated with pathological
immunity toward a protective Th2 response.
U.S. Patent No. 6,207,159
B1
U.C. Case No. 1997-561-4
Issued: March 27, 2001
THE
TREATMENT OF NARCOLEPSY WITH IMMUNOSUPPRESSANTS
Participating UCLA Researchers:
Jerome M. Siegel, Lisa N. Boehmer
The invention provides compositions and methods for treatment of narcolepsy
or isolated cataplexy. Such methods entail administering a therapeutically
effective regime of at least one immunosuppressive agent. The methods
are particularly useful for prophylactic and therapeutic treatment of
narcolepsy or isolated cataplexy.
U.S. Patent No. 6,204,245
B1
U.C. Case No. 1999-191-1
Issued: March 20, 2001
DEPOSITION
OF COATINGS USING AN ATMOSPHERIC PRESSURE PLASMA JET
Participating UCLA Researchers:
Steve E. Babayan, Robert F. Hicks
The use of a nonthermal source, which is capable of operation at 760 torr,
is demonstrated. As an example of the application of the present invention,
a helium/oxygen gas mixture is introduced into the annular region between
two coaxial electrodes driven by a 13.65 MHz radio frequency (rf) source
at between 40 and 500 W to produce a stable plasma jet. Silicon dioxide
films are deposited by introducing tetraethoxysilane (TEOS) into the effluent
stream. A deposition rate of 3020+/-250 A/min. is achieved with an rf
power of 400 W, 0.2 torr of TEOS, 11.1 torr of oxygen, 748.7 torr of helium,
and a total gas flow rate of 41 L/min. The deposition rate depends on
the oxygen partial pressure, the TEOS partial pressure, and the rf power
to the 0.28, 0.47, and 1.41 powers, respectively. However, increasing
the temperature decreases the deposition rate. The observed dielectric
constants of the films decrease from 5.0+/-0.2 to 3.81+/-0.03 as the deposition
temperature increases from 115 to 350 degrees Celsius. Infrared spectra
of the deposited films at 350 degrees Celsius show no carbon or hydroxyl
ion contamination, indicating excellent material purity.
U.S. Patent No. 6,194,036
B1
U.C. Case No. 1997-628-1
Issued: February 27,2001
METHODS
AND KITS FOR IDENTIFYING DUCTAL ORIFICES
Participating UCLA Researchers:
Sanford H. Barsky, Susan M. Love
Methods, kits, and apparatus for locating, labeling, and accessing breast
ducts are described. An orifice to one or more ductal networks is labeled
using a specific binding substance, typically an antibody, specific for
a tissue marker present on the orifice. Exemplary tissue markers include
those present on the ductal epithelium, such as cytokeratins, including
cytokeratin 8 and cytokeratin 18; E cadhedrin; and epithelial membrane
antigen. Labelling of the ductal orifices permits reliable identification
and access to each of the multiple ductal networks which may be present
in an individual breast.
U.S. Patent No. 6,168,779
B1
U.C. Case No. 1997-597-1
Issued: January 2, 2001
LOW-POWER
STATE-SEQUENTIAL VITERBI DECODER FOR CDMA DIGITAL CELLULAR APPLICATIONS
Participating UCLA Researchers:
Inyup Kang
A method, apparatus, and a program storage device useful in performing
computations to decode a convolutionally coded sequence without resorting
the use of switching elements is disclosed. The method comprises the steps
of computing a first branch metric between a first input node and an output
node, adding a first input path metric to the first branch metric to produce
a first candidate output pathe metric, computing a second branch metric
between a second input node and the output node, adding the second branch
metric to a second path metric to derive a second candidate output path
metric, and configuring a decision bit based upon the parity of the output
state node state and upon whether the first candidate output path metric
is greater than the second candidate output path metric. In one embodiment,
a comparison between the first and the second candidate output path metrics
is compared to the parity of the output node by an exclusive OR gate or
a table lookup to determine the decision bit. The invention also is described
by an apparatus comprising a means for performing these steps and a program
storage device tangibly embodying instructions to perform the steps.
U.S. Patent No. 6,163,581
U.C. Case No. 1997-550-2
Issued: December 19, 2000
COMPOSITIONS
AND METHODS FOR TREATING AND PREVENTING MICROBIAL AND VIRAL INFECTIONS
Participating UCLA Researchers:
Robert I. Lehrer, Sylvia S. L. Harwig, Vladimir N. Kokryakov
Peptide-based compounds containing four invariant cysteine residues which
have been optionally oxidized to contain two intramolecular disulfide
bonds, or modified forms where the cysteines are replaced are useful as
preservatives and in preventing, treating, or ameliorating viral or microbial
infection in animals and plants, and in inactivating endotoxin. These
compounds, in one embodiment, are of the formula: A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-(A17-A18)
and the N-terminal acylated and/or C-terminal amidated or esterified forms
thereof, which is either in the optionally -SH stabilized linear or in
a cystine-bridged form, wherein each of A1 and A9 is independently a small
amino acid; each of A2 and A3 is independently a basic amino acid; each
of A5, A7, A12, A14, and A16 is independently a hydrophobic amino acid;
A4 is a basic or a small amino acid; A10 is a basic or a small amino acid
or is proline; A11 is a basic or hydrophobic amino acid; A17 is not present
or, if present, is a small amino acid; A18 is not present or, if present,
is a basic amino acid;or a modified form of formula (1) and the N-terminal
acylated and/or C-terminal amidated or esterified forms thereof wherein
each of 1-4 cysteines is independly replaced by a hydrophobic amino acid
or a small amino acid.
U.S. Patent No. 6,159,936
U.C. Case No. 1993-540-E
Issued: December 12, 2000
SINGLE-ELECTRON
SOLID STATE ELECTRONIC DEVICE
Participating UCLA Researchers:
James R. Heath, Gil Markovich, Daniel V. Leff
A single-electron solid state electronic device is characterized by organically
functionalized nanometer size metal and metal alloy nanocrystal active
elements. The electronic behavior of the device is distinguished by single
electron charging phenomena, displaying characteristic Coulomb Blockade
and Coulomb Staircase signatures.
U.S. Patent No. 6,159,620
U.C. Case No. 1997-593-2
Issued: December 12, 2000
HUMAN
MINOR VAULT PROTEIN P193
Participating UCLA Researchers:
Leonard H. Rome, Valerie A. Kickhoefer
The present invention involves a protein consisting essentially of purified
human minor vault protein p193 or purified biologically active variants
thereof, or a combination of purified human minor vault protein p193 and
biologically active variants thereof. Also provided is a polynucleotide
molecule encoding a protein which consists essentially of human minor
valut protein p193, or its complementary strands. Further provided is
a method of diagnosing and a method of treating patients with multidrug
resistant cancer.
U.S. Patent No. 6,156,879
U.C. Case No. 1998-529-1
Issued: December 5, 2000
SIMULTANEOUS
MEASUREMENT OF FREE TRIIODOTHYRONINE AND FREE THYROXINE BY EQUILIBRIUM
DIALYSIS AND IMMUNOASSAY
Participating UCLA Researchers:
Inder J. Chopra
The present invention provides methods for the simultaneous measurement
of triiodothyronine (T3) and thyroxine (T4) in biological fluids such
as serum by direct equilibrium dialysis and immunoassay. Specifically,
the method comprises dialyzing the serum sample to equilibrium in a physiological
buffer system so that the free T3 and the free T4 are separated from T3
and T4 bound to serum proteins. The method further comprises combining
a measured quantity of the dialyzed serum sample having free T3 and free
T4 with reagents comprising a measured quantity of T3 labelled with a
detectable marker and a measured quantity of T4 labelled with a detectable
marker; an anti-T3 antibody of sufficient specificity and in sufficient
quantity to bind a measurable quantity of the free T4. The method then
comprises allowing reaction of the free T3 and the free T4 and the labelled
T3, and the labelled T4, with an anti-T3 antibody and the anti-T4 antibody
to proceed substantially to equilibrium to thereby produce antibody bound
labelled T3 and antibody bound labelled T4. Finally, the method comprises
separating the unbound labelled T3 from the antibody bound labelled T4;
and determining the levels of T3 and T4 in the sample by comparing relative
amounts of antibody bound labelled T3 and T4 and unbound labelled T3 and
T4. In one embodiment of this method, the assay is a radioimmunoassay.
U.S. Patent No. 6,153,440
U.C. Case No. 1998-568-1
Issued: November 28,2000
OUTER
MEMBRANE PROTEINS
Participating UCLA Researchers:
Ellen Shang, James N. Miller, David R. Blanco, Michael A. Lovett, Bruce
Kagan
The present invention presents three B. burgdorferi membrane proteins:
Oms28, Oms45, and Oms66, each of about 28, 45, and 66 kDa respectively;
and with average single channel conductances of about 0.6, 0.22, and 9.7
nS, respectively. Also disclosed are the methods for purifying these proteins
from B. burgdorferi, methods for producing antibodies to these
proteins, and the resulting antibodies. These proteins and their immunogenic
fragments, and antibodies capable of binding to them are useful for inducing
an immune response to pathogenic B. burgdorferi as well as providing
a diagnostic target for Lyme disease. Further disclosed are the nucleotide
and amino acid sequences, the cloning of the genes encoding the proteins
and their recombinant proteins, and methods for obtaining the foregoing.
Also included in the present invention are other B. burgdorferi
outer membrane proteins obtainable by the isolation and purification methods
of the present invention.
U.S. Patent No. 6,153,194
U.C. Case No. 1996-559-3
Issued: November 28, 2000
NUCLEOTIDE
SEQUENCE ENCODING OLIGODENDROCYTE-SPECIFIC PROTEIN
Participating UCLA Researchers:
Jeff M. Bronstein
A protein consisting essentially of purified oligodendrocyte-specific
protein of purified biologically active variants thereof, or a combination
of purified oligodendrocyte-specific protein and biologically variants
thereof. A purified and isolated peptide having the sequence Ala-Lys-Tyr-Arg-Arg-Ala-Gln-Leu-Ala-Gly,
residues 115-124 of SEQ ID NO:2.
U.S. Patent No. 6,150,136
U.C. Case No. 1996-532-2
Issued: November 21, 2000
OLIGODENDROCYE-SPECIFIC
PROTEIN
Participating UCLA Researchers:
Jeff M. Bronstein
A protein consisting essentially of purified oligodendroyte-specific protein
or purified biologically active variants thereof, or a combination of
purified oligodendrocyte-specific protein andbiologically active variants
thereof. A purified and isolated peptide having the sequence Ala-Lys-Tyr-Arg-Ala-Gln-Leu-Ala-Gly,
residues 115-124 of SEQ ID NO:2. A device for identifying an epitope region
of a peptide, protein, or protein homologue of interest comprising a polypropylene
membrane having a plurality of sequentially oriented peptide spots, each
spot containing a peptide having an amino acid sequence where the amino
acid sequences of the peptides on the peptide spots sequentially progress
through the amino acid sequence of the peptide, protein, or protein homologue
of interest. A method of diagnosing multiple sclerosis and a method of
treating multiple sclerosis. A method of diagnosing a disease or condition,
such as an autoimmune disease, the disease or condition having the clinical
feature of antibody production against a peptide, protein, or protein
homologue.
U.S. Patent No. 6,147,191
U.C. Case No. 1996-532-3
Issued: November 14, 2000
LEPTOSPIRAL
OUTER MEMBRANE PROTEIN, LIPL46
Participating UCLA Researchers:
David A. Haake
An antigenic preparation is provided containing an outer membrane protein
associated with pathogenic strains of Leptospira. The protein has
been designated "LipL46" for "lipoprotein from Leptospira"
and because the isolated polypeptide migrates to a position corresponding
to a molecular weight of 46 kD in a denaturing polyacrylamide gel. The
invention provides polynucleotides encoding LipL46 and antibodies that
bind the protein which are useful in the diagnosis of leptospirosis. In
addition, LipL46 can be used immunologically as a vaccine for spirochete-associated
pathologies.
U.S. Patent No. 6,140,083
U.C. Case No. 1998-560-1
Issued: October 31, 2000
ENDODERM,
CARDIAC AND NEURAL INDUCING FACTORS
Participating UCLA Researchers:
Edward De Robertis
Two novel proteins have been designated "Cerberus" and "frzb-1,"
respectively. Cerberus is expressed as a secreted peptide during embryogenesis
of the Xenopus embryo, and is expressed specifically in the head
organizer region. This new molecule has endodermal, cardiac, and neural
tissue inducing activity, that should prove useful in therapeutic, diagnostic,
and clinical applications requiring regeneration, differentiation, or
repair of these and other tissues. Frzb-1 is a soluble antagonist of growth
factors of the Wnt family that acts by binding to Wnt growth factors in
the extracellular space. A third novel protein is designated "PAPC"
which promotes the formation of dorsal mesoderm and somites in the embryo.
U.S. Patent No. 6,133,232
U.C. Case No. 1996-592-2
Issued: October 17, 2000
MOLECULAR
WIRE CROSSBAR MEMORY
Participating UCLA Researchers:
James R. Heath
A molecular wire crossbar memory (MWCM) system is provided. The MWCM comprises
a two-dimensional array of a plurality of nanometer-scale devices, each
device comprising a junction formed by a pair of crossed wires where one
wire crosses another and at least one connector species connecting the
pair of crossed wires in the junction. The connector species comprises
a bi-stable molecular switch. The junction forms either a resistor or
a diode or an asymmetric non-linear resistor. The junction has a state
that is capable of being altered by application of a first voltage and
sensed by application of a second, non-destructive voltage.
U.S. Patent No. 6,128,214
U.C. Case No. 1999-282-1
Issued: October 3, 2000
INDWELLING
HEAT EXCHANGE CATHETER AND METHOD OF USING SAME
Participating UCLA Researchers:
Yves Pierre Gobin
A catheter is adapted to exchange heat with a body fluid, such as blood,
flowing in body conduit, such as a blood vessel. The catheter includes
a shaft with a heat exchange region disposed at its distal end. This region
may include at least one balloon adapted to receive a remotely cooled
heat exchange fluid, preferably flowing in a direction counter to that
of the body fluid. Embodiments including multiple balloons enhance the
surface area of contact, and the mixing of both the heat exchange and
the body fluid. The catheter can be positioned to produce hypothermia
in a selective area of the body without cooling the entire body system.
It is of particular advantage in brain surgeries where stroke, trauma
or cryogenic tumors can best be addressed under hypothermic conditions.
U.S. Patent No. 6,126,684
U.C. Case No. 1999-501-1
Issued: October 3, 2000
PROCESS
FOR RAPID SOLID-STATE FORMATION OF REFRACTORY NITRIDES
Participating UCLA Researchers:
Richard B. Kaner
A process for forming high quality crystalline refractory materials, particulary
gallium (I11) nitride (GaN), from solid precursors. By blending dry reactants
in an oxygen and moisture free environment, placing the reactants in a
sealed vessel, pressurizing the reactants to in excess of 5 kilobars (5000
atmospheres) and rapidly exposing the reactants to a temperature in excess
of about 225 degrees C. The soluble salt by-products are then extracted
from the resultant mixture, leaving high purity crystals of the nitride
in the form of a fine powder.
U.S. Patent No. 6,120,748
U.C. Case No. 1997-508-2
Issued: September 19, 2000
HIGH
RESOLUTION SCINTILLATION DETECTOR WITH SEMICONDUCTOR READOUT
Participating UCLA Researchers:
Craig S. Levin, Edward J. Hoffman
The invention involves a novel high resolution scintillation detector
array for use in radiation imaging such as high resolution Positron Emission
Tomography (PET.) It comprises one or more parallel-epiped crystals with
at least one long surface of each crystal being in intimate contact with
a semiconductor photodetector such that photons generated within each
crystal by gamma radiation passing therethrough is detected by the photodetector
paired therewith.
U.S. Patent No. 6,114,703
U.C. Case No. 1996-511-1
Issued: September 5, 2000
ELECTRICALLY
ADDRESSABLE VOLATILE NON-VOLATILE MOLECULAR-BASED SWITCHING DEVICES
Participating UCLA Researchers:
James Richard Heath, Gunter Mattersteig, Francisco M. Raymo, James
Fraser Stoddart, Eric Wong
The invention involves volatile and non-volatile solid state molecular
switching devices which are electrically addressable and may be used in
memory cells, routing circuits, inverters and field programmable devices
which may or may not be designed to exhibit diode behavior. The molecular
switching devices include certain [2] catenanes as bistable molecules
which are sandwiched between two switch terminals. The switches are extremely
small and have dimensions which range from several microns down to a few
nanometers.
U.S. Patent No. 6,198,655
B1
U.C. Case No. 2000-114-1
Issued: March 6, 2001
HUMAN
VAULT RNA
Participating
UCLA Researchers:
Leonard H. Rome, Valerie A. Kickhoefer
The present invention
involves a polynucleotide encoding a human vault-associated vRNA or its
complementary strand. A purified and isolated polynucleotide molecule
consisting essentially of a human vault RNA, or its complimentary strands,
or a combination of a nucleotide sequence consisting essentially of a
human vault RNA and its complimentary strands. Also disclosed is a method
of diagnosing a patient with a multidrug-resistant cancer and a method
of treating a patient with multidrug-resistant cancer. Provided finally
are a composition for treating multidrug-resistant cancer comprising a
polynucleotide which hybridizes with a human vault-associated vRNA, and
a method of screening for compositions effective in multidrug-resistant
cancer.
U.S. Patent No. 6,110,740
U.C. Case No. 1995-597-2
Issued: August 29, 2000
PSA
POSITIVE REGULATING (PSAR) SEQUENCES AND USES THEREOF
Participating UCLA Researchers:
Shen Pang, Arie S. Belldegrun
The present invention provides an isolated nucleic acid molecule which
is a PSA positive regulatory sequence (PSAR). This molecule has been deposited
with the ATCC.
U.S. Patent No. 6,110,702
U.C. Case No. 1998-510-2
Issued: August 29, 2000
MICE
MODELS OF HUMAN PROSTATE CANCER PROGRESSION
Participating UCLA Researchers:
Charles L. Sawyers, Karen A. Klein, Owen N. Witte, Robert E. Reiter
The present invention provides an immune deficient mouse having a human
prostate xenograft of locally advanced or metastatic prostate cancer and
uses thereof.
U.S. Patent No. 6,107,540
U.C. Case No. 1996-540-2
Issued: August 22, 2000
ORGANICALLY-FUNCTIONALIZED
MONODISPERSE NANOCRYSTALS OF METALS
Participating UCLA Researchers:
James R. Heath, Daniel V. Leff
Organically functionalized metal nanoparticles are produced by mixing
a metal precursor with an organic surface passivant and reacting the resulting
mixture with the reducing agent to generate free metal while binding the
passivant to the surface of the free metal to produce organically functionalized
metal particles.
U.S. Patent No. 6,103,868
U.C. Case No. 1995-560-2
Issued: August 15, 2000
INSTANTANEOUS
SYNTHESIS OF REFRACTORY NITRIDES FROM SOLID PRECURSORS
Participating UCLA Researchers:
Richard B. Kaner
The invention involves a process for forming high quality crystalline
refractory materials, particulary gallium (I11) nitride (GaN), from solid
precursors. This process includes blending dry reactants, including NH4Cl,
in an oxygen and moisture free environment, placing the reactants in a
reaction vessel and in an inert environment, and rapidly exposing the
reactants to a temperature in excess of about 225 degrees C. The soluble
salt by-products are then extracted from the resultant mixture, leaving
high purity crystals of the nitride in the form of a fine powder.
U.S. Patent No. 6,096,282
U.C. Case No. 1997-508-3
Issued: August 1, 2000
E25A
PROTEIN, METHODS FOR PRODUCTION AND USE THEREOF
Participating UCLA Researchers:
Robert E. Reiter, Owen N. Witte, Charles L. Sawyers
The invention provides a human E25a protein which is upregulated in cancerous
cells, including those of hormone refractory prostate cancer, colon cancer,
breast cancer or other cancers of epithelial origin. The invention also
provides nucleic acid molecules encoding E25a protein, nucleic acid probes
which hybridize with nucleic acid molecules encoding E25a protein and
its related molecules can be useful as diagnostic markers of cancer, and
as specific therapeutic targets in this disease. The invention also provides
methods for diagnosing cancer, including hormone refractory prostate cancer.
U.S. Patent No. 6,093,800
U.C. Case No. 1997-513-2
Issued: July 25, 2000
PRODRUGS
OF PROTON PUMP INHIBITORS
Participating UCLA Researchers:
Michael E. Garst, George Sachs, Jai Moo Shin
Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump
inhibitor drugs have a hydrolysable sulfinyl or arylsufonyl group attached
to the benzimidazole nitrogen, or include a group that forms a Mannich
base with the benzimidazole nitrogen. The prodrugs of the invention hydrolyze
under physiological conditions to provide the proton pump inhibitors with
a half life measurable in hours, and are capable of providing sustained
plasma concentrations of the proton pump inhibitor drugs for longer time
than presently used drugs. The generation of the proton pump inhibitor
drugs from the prodrugs of the invention under physiological conditions
allows for more effective treatment of several diseases and conditions
caused by gastric acid secretion.
U.S. Patent No. 6,093,734
U.C. Case No. 2000-338-1
Issued: July 25, 2000
TREATMENT
OF RHEUMATOID ARTHRITIS BY ORAL ADMINISTRATION OF POOLED HUMAN IMMUNOGLOBULIN
Participating UCLA Researchers:
Richard Weisbart
Pooled human immunoglobulin may be administered orally to rheumatoid arthritis
patients to treat the rheumatoid arthritic condition of those patients.
Oral administration of pooled human immunoglobulin can result in significant
clinical improvement in the level of disease activity in patients with
rheumatoid arthritis.
U.S. Patent No. 6,090,380
U.C. Case No. 1993-544-2
Issued: July 18, 2000
ENDOVASCULAR
ELECTROLYTICALLY DETACHABLE WIRE AND TIP FOR THE FORMATION OF THROMBUS
IN ARTERIES, VEINS, ANEURYSMS, VASCULAR MALFORMATIONS AND ARTERIOVENOUS
FISTULAS
Participating UCLA Researchers:
Guido Gugliemi, Ivan Sepetka
An artery, vein, anerysm, vascular malformation or arterial fistula
is occluded through endovascular occlusion by the endovascular insertion
of a platinum wire and/or tip into the vascular cavity. The vascular cavity
is packed with the tip to obstruct blood flow or access of blood in the
cavity such that the blood clots in the cavity and an occulusion is formed.
The tip may be elongate and flexible so that it packs the cavity by being
folded upon itself a multiple number of times, or may pack the cavity
by virtue of a filamentary or fuzzy structure of the tip. The tip is then
separated from the wire mechanically or by electrolytic separation of
the tip from the wire. The wire and the microcatheter are thereafter removed
leaving the tip embedded in the thrombus formed within the vascular cavity.
Movement of wire in the microcatheter is more easily tracked by providing
a radioopaque proximal marker on the microcatheter and a corresponding
indicator marker on the wire. Electrothrombosis is facilitate by placing
the ground electrode on the distal end of the microcatheter and flowing
current between the microcatheter electrode and the tip.
U.S. Patent No. 6,083,220
U.C. Case No. 1989-203-8
Issued: July 4, 2000
|